

DIFFUSION PHARMACEUTICALS WINS 2012 VA HEALTHCARE INNOVATORS AWARD

CHARLOTTESVILLE, VA – June 7, 2012 – Diffusion Pharmaceuticals LLC of Charlottesville today won the Virginia Healthcare Innovators award in the “Medical Product or Device ” category for development of lead drug candidate trans sodium crocetinate (TSC). TSC is being developed as a treatment for life threatening solid tumors by altering the diffusion of oxygen in hypotoxic tumor tissue without adversely affecting normal tissue. The drug recently entered an accelerated Phase 2 clinical trial in patients with GBM type brain cancer at University of Virginia Medical Center, the lead institution among 15 participating cancer centers nationwide.

David Kalergis, CEO, accepted the award for the company before hundreds gathered in Richmond for the 2012 Annual Virginia Healthcare Innovators conference. Kalergis credited the foundational discoveries of the mechanism of action by Professor Emeritus John Gainer at UVa, and the Charlottesville and Virginia scientific and business community for supporting and enabling the company’s development of this important novel treatment.

Diffusion Pharmaceuticals, LLC of Charlottesville, received the award for the development of a new drug trans sodium crocetinate (TSC) for treatment of solid tumors, including brain tumors, by a novel mechanism of action, altering the diffusion of oxygen in hypotoxic tumor tissue without adversely affecting normal tissue.